Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.47 |
| ▸ | MERTK | Q12866 | 4/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 7/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20779812 | 0.80 | OPRK1 (0.38) | AXLMERTKJAK2KCNH2 | |
| SCHEMBL20779645 | 0.80 | IRAK1 (0.41) | IRAK1IRAK4 | |
| SCHEMBL20766946 | 0.79 | BRD4 (0.55) | AXLIRAK1MERTKTYRO3TTK | |
| SCHEMBL29901795 | 0.79 | BRD4 (0.55) | AXLIRAK1MERTKTYRO3TTK | |
| SCHEMBL20779484 | 0.77 | TTK (0.51) | AXLIRAK1MERTKTYRO3TTK | |
| SCHEMBL25043144 | 0.76 | BRD4 (0.49) | — | |
| SCHEMBL28419033 | 0.71 | CHEK1 (0.48) | AXLIRAK4CHEK1 | |
| SCHEMBL20384219 | 0.71 | ALDH1A1 (0.43) | — | |
| SCHEMBL20779774 | 0.71 | ROCK2 (0.39) | LRRK2 | |
| SCHEMBL20779646 | 0.71 | OPRK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |